ResultsIQ

ResultsIQ › Latest results › Bajaj Healthcare Limited

Bajaj Healthcare Limited Q2 FY26 results press release summary

NSE: BAJAJHCARE · BSE: 539872

Results press release of 17 Oct 2025, summarised by AI from the filing.

Gross margin expanded by 462 basis points sequentially to 50.8%; EBITDA margin improved by 217 basis points to 19.1%.

Key takeaways

  1. Margin expansion Gross margin expanded by 462 basis points sequentially to 50.8%; EBITDA margin improved by 217 basis points to 19.1%.
  2. Regulatory progress SEC-CDSCO recommendation for Suvorexant Phase III trials; DCGI approval for Cenobamate Phase III trials, currently underway.
  3. Pricing pressure Pricing pressure persists in the domestic API segment.

Original filing on BSE

Bajaj Healthcare Limited Q1 FY27 results

As filed: Revenue ₹166 cr (+11% year on year), EBITDA ₹28.8 cr (+15% year on year), PAT ₹13.7 cr (+14% year on year), EBITDA margin 17.4% (+58 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹153 cr (−1% year on year), EBITDA ₹22.7 cr (+89% year on year), PAT −₹22.9 cr (+4% year on year), EBITDA margin 14.8% (+703 bps). Score 54 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well above it; profit before exceptional items growth was well below it. EBITDA margin rose 703 bps year on year. Revenue fell 5% from last quarter. Profit before exceptional items rose ₹0.4 cr on a year ago, against ₹3.0 cr the year before. Share price after the results: −12.8% in 28 days (Nifty 500: −2.8%).
  • Q3 FY26: Revenue ₹161 cr (+31% year on year), EBITDA ₹30.7 cr (+33% year on year), PAT ₹15.7 cr (+31% year on year), EBITDA margin 19.0% (+32 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 32 bps year on year. Revenue rose ₹38.2 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: −7.9% in 28 days (Nifty 500: −0.7%).
  • Q2 FY26: Revenue ₹148 cr (+11% year on year), EBITDA ₹27.0 cr (+13% year on year), PAT ₹11.0 cr (+22% year on year), EBITDA margin 18.2% (+20 bps). Score 56 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 20 bps year on year. Profit fell 8% from last quarter. Share price after the results: −4.7% in 28 days (Nifty 500: +1.0%).
  • Q1 FY26: Revenue ₹149 cr (+13% year on year), EBITDA ₹25.0 cr (+4% year on year), PAT ₹12.0 cr (+71% year on year), EBITDA margin 16.8% (−140 bps). Score 46 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend. EBITDA margin fell 140 bps year on year. Tax rate 13%. Revenue fell 3% from last quarter. Share price after the results: −17.9% in 29 days (Nifty 500: −0.3%).
  • Q4 FY25: Revenue ₹154 cr (+15% year on year), EBITDA ₹12.0 cr (−25% year on year), PAT ₹11.0 cr, EBITDA margin 7.8% (−415 bps). Score 19 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it. EBITDA margin fell 415 bps year on year. Other income 117% of PBT. Tax rate 0%. Profit fell 8% from last quarter. Share price after the results: −11.9% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹123 cr (+13% year on year), EBITDA ₹23.0 cr (+21% year on year), PAT ₹12.0 cr, EBITDA margin 18.7% (+127 bps). Score 58 of 100, In line with trend. EBITDA margin rose 127 bps year on year. Tax rate -25%. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter.
  • Q2 FY25: Revenue ₹133 cr (+32% year on year), EBITDA ₹24.0 cr (+26% year on year), PAT ₹9.0 cr, EBITDA margin 18.1% (−77 bps). Score 71 of 100, Above trend. EBITDA margin fell 77 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Bajaj Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.